A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D Index
Mara Persano(Vita-Salute San Raffaele University), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Margherita Rimini(Vita-Salute San Raffaele University), Anna Saborowski(Medizinische Hochschule Hannover), Fabian Finkelmeier(Goethe University Frankfurt), Federica Lo Prinzi(Campus Bio Medico University Hospital), Alessandro Parisi(Marche Polytechnic University), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Ricardo Roque, Giovanni Farinea(University of Turin), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Mario Scartozzi(University of Cagliari), Stephen L. Chan(Chinese University of Hong Kong), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Laura Passeri(Vita-Salute San Raffaele University), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Hong Jae Chon(CHA University Bundang Medical Center), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ingrid Garajová(University of Parma), Chiara Pircher(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Cecilia Melo Alvim(Hospital de Santa Maria), Aitzaz Qaisar, Tomoyuki Satake(National Cancer Center Hospital East), Frederik Peeters, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Changhoon Yoo(Ulsan College), Jin Won Kim(Seoul National University Bundang Hospital), Il Hwan Kim(Inje University Haeundae Paik Hospital), Chiara Pirrone(Ospedale Policlinico San Martino), Silvana Leo(Ospedale Vito Fazzi), Nuno Couto(Champalimaud Foundation)
Cited by 9
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k